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Abstract
Background. The goal of our study was to investigate the content and particularities of change of vascular endothe-
lial growth factor-A (VEGF-A) levels as a marker of endothelial dysfunction (ED) in patients with hypertension 
(HT) with or without type 2 diabetes mellitus (T2DM) and with or without subclinical hypothyroidism (SH). 
Material and methods. Two hundred and eleven patients with hypertension stage II were divided into 3 groups: 
Group 1 — with HT (n = 55); Group 2 — with AH and T2DM (n = 97); Group 3 — with HT, T2DM and SH 
(n = 59). The patients in Group 3 were divided into 3 subgroups depending on TSH levels: 3a (n = 26) — TSH 
4.0–6.0 mIU/L; 3b (n = 20) — TSH 6.1–8.0 mIU/L; 3c (n = 13) — TSH 8.1–10.0 mIU/L. We evaluated lipids, 
carbohydrate metabolism, serum insulin concentration, insulin resistance index — HOMA, and the level of 
VEGF-A in plasma.
Results. The levels of VEGF-A in Group 2 was significantly lower vs. Group1 (323.94 ± 22.17 pg/mL 
and 413.15 ± 29.02 pg/mL, respectively (p < 0.05)). The patients in Group 3d had lower VEGF-A levels than 
the patients in Group 1, but higher than those in Group 2. Among Group 3 patients, the levels of VEGF-A 
were the lowest in the 3a subgroup (375.91 ± 19.81 pg/mL), significantly different from 3b and 3c subgroups 
(p < 0.05), for which no differences were found (p > 0.05.). In the 3a subgroup VEGF-A levels were signifi-
cantly higher than in Group 2 patients (p < 0.05).
Conclusion. These data confirms the hypothesis of increasing ED in hypothyroidism even at the subclinical level.
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Introduction
In recent years studies have convincingly proved an 
important and independent role of the endothelium 
in the development of cardiovascular (CV) diseases. 
It plays an extremely important role in the develop-
ment of atherosclerotic changes in the vascular wall, 
vessel remodeling and angiogenesis [1, 2]. Endotheli-
al dysfunction (ED) has proved to be associated with 
a large number of different factors and pathological 
conditions such as age, postmenopause, hypercho-
lesterolemia and hypertriglyceridemia, diabetes mel-
litus, smoking, and arterial hypertension (HT). It is 
important that the risk of ED development increases 
both because of an increase in the total number of 
risk factors (RF) and their combination.
There are a large number of ED plasma markers. 
One of the recognized ED biomarkers is vascular 
endothelial growth factor A (VEGF-A). There is evi-
dence that VEGF-A plays an important role in CV 
diseases, in particular in hypertension it promotes 
vascular wall remodeling [2, 3]. It is believed, that 
detection of this indicator in serum is the earliest 
marker for ED development, when even active intra-
vascular inflammation has not yet begun. VEGF-A 
is an important bioactive substance involved in the 
development of vascular complications in diabetes 
mellitus (DM). However, currently available data 
on VEGF-A levels in DM and its complications 
are quite controversial. Some studies describe both 
the increase and the decrease in VEGF-A levels in 
DM. VEGF-A has been successfully used to treat 
ischemia with diabetic limb lesions. On the other 
hand, inhibition of VEGF-A was used in diabetic 
retinopathy [4].
For several decades HT has taken the leading place 
among CV diseases. It is worth noting that today 
isolated HT is relatively infrequent. Usually, clini-
cians have to deal with clinical situations when HT 
is associated with other diseases, in particular with 
endocrinopathies, primarily with DM and thyroid 
diseases, whose number in Ukraine is constantly in-
creasing.
It is believed that, along with type 2 diabetes 
mellitus (T2DM), hypothyroidism, including sub-
clinical (SH), makes a significant contribution to the 
formation of cardiometabolic RFs, which determine 
the prognosis for AH, coronary heart disease (CHD), 
and other conditions. It is believed that HT and car-
bohydrate metabolism disorders are pathogenetically 
interrelated. It is likely that their pathological effects 
are also realized through ED.
There is no doubt that the mechanisms of ED 
development in comorbid pathology are complicated 
and insufficiently studied [1]. Of particular interest 
is the study of comorbid conditions, each of which is 
characterized by the presence of ED in the pathogen-
esis and factors that exacerbate it, which may mani-
fest itself in the enhancement of VEGF-A expression 
and obviously play an important role in understand-
ing the commonality of pathogenetic processes and 
developing more effective preventive and therapeutic 
measures.
The purpose of our study was to determine the 
levels and features of VEGF-A as a marker of endo-
thelial dysfunction in patients with hypertension in 
combination with T2DM and SH.
We will test the hypothesis that hypothyroidism 
(even subclinical) will increase in ED.
Material and methods
The study included 211 patients (83 males and 
128 females) aged 40 to 75 (mean age 59.4 ± 3.7 
years) with HT stage II. All patients were divided 
into 3  groups according to comorbidity: Group 1 
— 55 patients with isolated HT (comparison group); 
Group 2 — 97 patients with AH in combination 
with T2DM; Group 3 — 59 patients with HT in 
combination with T2DM and SH. An obligatory 
criterion for patients of the Group 3 was SH devel-
oped as a result of autoimmune thyroiditis (AIT); 
T2DM was well controlled in all diabetic patients. 
The control group consisted of 20 healthy individu-
als, matched for age and sex. 
Exclusion criteria were symptomatic hyperten-
sion, uncontrolled hypertension, type 1 diabetes and 
other endocrine disorders, clinical signs of coronary 
heart diseases or severe concomitant chronic diseases. 
Also, exclusion criteria were taking iodine medica-
tions, glucocorticoids, amiodarone, lithium medica-
tions, medication containing estrogens, pregnancy, 
patients with a previously diagnosed manifested 
hypothyroidism or SH, patients receiving hormone 
replacement therapy after surgical treatment of thy-
roid gland.
In all patients hypertension was confirmed using 
the European Society of Hypertension (ESH) and 
the European Society of Cardiology (ESC) guide-
lines (2018) [5].The diagnosis of SH and T2DM 
was established in accordance with the approved 
Order of the Ministry of Health of Ukraine No. 
356 dated May 22, 2009 On approval of protocols 
for the provision of medical care to patients with en-
docrine diseases [6], Order of the Ministry of Health 
of Ukraine No. 1118 dated December 21, 2012 On 
Approval and implementation of medical-technological 
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documents for the standardization of medical aid in 
type 2 diabetes [7] and in accordance with the Eu-
ropean Thyroid Association (ETA, 2013) and the 
American Diabetes Association and the European 
Association for the Study of Diabetes (2015) guide-
lines [8, 9].
All patients received basic therapy in accordance 
with international and national guidelines for the 
management of patients with the corresponding pa-
thology [5–9], on a background of dietary recom-
mendations. All patients had received antihyperten-
sive therapy for at least 6 months before they were 
included in the study and received an individually-
selected dose of an angiotensin-converting enzyme 
inhibitor or angiotensin II receptor blocker (ACE 
inhibitors/ARB) and a diuretic (indapamide); some 
of the patients additionally received a calcium an-
tagonist (amlodipine or lercanidipine). As an anti-
diabetic therapy, patients with T2DM received met-
formin in individually-selected doses from 1000.0 to 
2000.0 mg/day; 5 patients (3.21%) additionally used 
an agonist of glucagon-like peptide-1 (GLP-1) and 
3 patients (1.92%) — an inhibitor of type 2 sodium-
glucose transporter (SGLT2).
All patients underwent anthropometric measure-
ments [height, body weight, body mass index (BMI) 
according to the Kettle index: BMI = weight (kg)/
/height (m2)].
The diagnosis of SH was established when the 
thyroid stimulating hormone (TSH) levels were 
found on two separate occasions with an interval 
of 3 or 6 months to exceed the upper limit of the 
reference range (4.0 mIU/L), on the background of 
normal levels of free thyroxine (fT4) and free triio-
dothyronine (fT3). Serum thyroid hormone levels 
were determined by immunoassay method with SPL 
Granum kits (Ukraine). Ultrasound examination of 
the thyroid gland was performed according to the 
standard method on the LOGIQ 5 device.
The arterial blood pressure level (BP) was evalu-
ated based on the average of three measurements at 
2-minute intervals in sitting position. Glucose con-
centration determination was performed by glucose 
oxidase method on the Humolizer analyzer (made 
in Germany). Determination of the total cholesterol 
level (TC), triglycerides (TG) and high-density li-
poprotein cholesterol (HDL-cholesterol) were per-
formed in serum using the enzyme photocolorimetric 
method with sets produced by Human (Germany). 
The content of low density lipoprotein cholesterol 
(LDL-cholesterol) was calculated by the Friedewald 
W.T. formula with consideration of measurement in 
mmol/L: LDL-cholesterol = TC – (HDL-cholesterol +
+ TG/2.22).
Concentration of insulin in serum was measured 
by the method of enzyme immunoassay (ELISA) 
using diagnostic kits DRG Instrument Gmbh (Ger-
many) on a semi-automatic enzyme immunoassay 
analyzer ImmunoChem-2100, High Technology, 
Inc. (USA).
To determine the insulin resistance (IR) index, 
HOMA-IR was used, which was calculated by the 
formula: [(glucose fasting) × (fasting insulin)] mmol/
/mL/22.5. 
The level of glycated hemoglobin (HbA1c) was 
determined by the immune enzyme method using 
“Hummer” kits (USA).
The condition of the vascular endothelium was 
studied by determining the level of VEGF-A in 
blood plasma by enzyme immunoassay (ELISA) us-
ing diagnostic kits from IBL International Gmbh 
(Germany) on a semi-automatic immunoassay mi-
croplate analyzer ImmunoChem-2100, High Tech-
nology, Inc. (USA).
The obtained results are presented as the average 
value of parameters (M) and standard error (m). 
Processing of statistical data was performed using 
the software package Statistics for Windows 8.0. The 
Student’s criterion and Pearson’s chi-squared test 
were used to evaluate the differences between groups 
in the distribution close to normal. A p-value < 0.05 
was considered statistically significant. To determine 
the effect of VEGF-A on various factors in observed 
patients, analysis of variance was used.
The study was performed in compliance with the 
basic provisions of the Helsinki Declaration of the 
World Medical Association on ethical principles of 
scientific and medical research involving human 
(1964–2000) and the order of the Ministry of Health 
of Ukraine No. 690 dated September 23, 2009. The 
study was approved by the Bioethics Commission 
at the Kharkiv National Medical University in ac-
cordance with the principles set forth in the Helsinki 
Declaration. The article is a fragment of the research 
work of the Department of Clinical Pharmacolo-
gy and Internal Medicine of the Kharkiv National 
Medical University “Optimization of diagnosis and 
treatment of comorbid pathology (hypertension and 
type 2 diabetes mellitus) on the basis of evaluation 
of cardio-hemodynamic, metabolism and pharma-
cogenetic analysis” Registration No. 0118U000923.
Results
Selected patients regularly used standard antihy-
pertensive therapy, which was the study inclusion 
criterion. Therefore, there were no significant dif-
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ferences between the groups in the mean values of 
both systolic blood pressure (SBP) and diastolic 
blood pressure (DBP), despite different comorbidi-
ties (Tab. I).
Patients in all studied groups had hypercholes-
terolemia. The presence of comorbid pathology in 
the form of a combined course of hypertension and 
T2DM in patients of the Group 2 was accompanied 
by a more pronounced dyslipidemia than in patients 
with isolated HT (Group 1). The attachment of SH 
to HT and T2DM was accompanied by the emer-
gence of a tendency for the growth of all investigative 
indexes of lipid metabolism (see Tab. I).
Analysis of carbohydrate metabolism parameters 
showed the sings of IR in all studied patients groups. 
In our study, despite the existence of significant dif-
ferences between the study subjects and the control 
group, the plasma insulin levels remained within the 
reference values [Groups 1, 2, 3, respectively: 17.46 ±
± 2.07 μM/mL, 22.34 ± 3.44 μM/mL; 20.06 ±
± 3.21 μM/mL; control group — 9.8 ± 1.16 μM/
/mL (p < 0.05)]. 
The analysis of VEGF-A in patients with isolated 
hypertension showed a significantly higher levels of 
this parameter than in the control group [413.15 ± 
± 29.05 pg/mL and 127.50 ± 21.88 pg/mL, respec-
tively (p < 0.05)]. Patients with combined course 
of hypertension and T2DM had significantly lower 
VEGF-A levels compared to patients with isolated 
HT [323.94 ± 22.17 pg/mL and 413.15 ± 29.05 
pg/mL, respectively (p < 0.05)], but significantly 
higher than in the control group (p < 0.05). In 
patients with combined course of HT, T2DM and 
SH, the level of VEGF-A (398.06 ± 36.82 pg/mL) 
was significantly higher than in controls (p < 0.05), 
not significantly lower than in Group 1 patients 
(p > 0.05) and significantly higher than in Group 2 
patients (p < 0.05). The results of analysis of variance 
showed a significant influence of VEGF-A on insulin 
(p < 0.001) and HOMA-IR index (p = 0.036) in 
patients with HT, T2DM and SH, whereas in other 
investigated groups no significant effect of VEGF-A 
on the studied parameters was detected. Taking into 
account the aggravation of most of the typical SH 
disturbances with the increase in TSH, its range of 
4.0–10.0 mU/L is large enough and may contain 
levels of great importance for specific categories of 
patients. Based on this assumption, all patients of 
Group 3 were divided into 3 subgroups in order 
to clarify the influence of TSH levels on the lev-
els of VEGF-A. Group 3a (n = 26) — TSH levels 
4.0–6.0 mIU/L; group 3b (n = 20) — TSH levels 
6.1–8.0 mIU/L; and group 3c (n = 13) — TSH 
levels 8.1–10 mIU/L. Despite the fact that such 
distribution of patients is clinically inexpedient, 
VEGF-A levels differed (Fig. 1).
Plasma levels of VEGF-A were the lowest in 3a 
subgroup (375.91 ± 19.81 pg/mL), significantly 
different from 3b and 3c subgroups (p < 0.05), 
for which practically no differences were found 
(3b — 416.31 ± 17.64 pg/mL, 3c — 414.68 ± 19.24 
pg/mL, respectively, p > 0.05.) These data coincide 
with the opinion of a number of authors who con-
sider the levels of TSH of 6–7 mIU/L as the thresh-
Table I. Selected characteristics of the study groups (M ± m)
Parameter Control(n = 20)
Group 1
(n = 55)
Group 2
(n = 97)
Group 3
(n = 59)
SBP [mm Hg] 125.2 ± 3.8 139.4 ± 6.61 145.5 ± 3.31 150.6 ± 5.81
DBP [mm Hg] 78.2 ± 7.1 88.4 ± 5.6 94.3 ± 4.21 96.3 ± 5.71
BMI [kg/m2] 22.12 ±  2.51 26.46 ± 1.211 29.52 ± 1.032 33.01 ± 2.141, 2, 3
TSH [mIU/L] 2.1 ± +0.53 2.1 ± 0.68 2.48 ± 0.79 6.51 ± 1.841, 2, 3
TC [mmol/L] 4.77 ±  0.52 5.29 ± 0.81 5.66 ± 0.93 5.93 ± 0.96
LDL-cholesterol [mmol/L] 2.6  ±  0.33 2.91 ± 0.61 3.06 ± 0.11 3.58 ± 0.73
HDL-cholesterol [mmol/L] 1.49 ± 0.30 1.26 ± 0.06 1.19 ± 0.12 1.15 ± 0.08
TG [mmol/L] 1.00 ± 0.30 1.63 ± 0.121 1.78 ± 0.211 2.34 ± 0.231, 2, 3
Blood fasting glucose [mmol/L] 4.63 ± 0.52 5.36 ± 0.17 8.02 ± 0.621, 2 7.47 ± 0.811, 2
Insulin fasting [μIU/mL] 9.8 ± 1.16 17.46 ± 2.071 22.34 ± 3.441 20.06 ± 3.211 
HbA1c (%) 4.62+1.08 5.81 ± 0.38 7.16+1.081 7.27 ± 1.871
HOMA-IR 2.23 ±  0.36 4.07 ± 0.591 8.17 ± 1.371, 2 6.34 ± 1.531, 2
VEGF-A [pg/mL] 127.50 ± 21.88 413.15 ± 29.051, 3 323.94 ± 22.171 398.06 ± 26.821, 3
TC — total cholesterol; LDL-cholesterol — low-density lipoprotein cholesterol; HDL-cholesterol — high-density lipoprotein cholesterol; TG — triglycerides; SBP — systolic blood pressure; DBP — diastolic blood pressu-
re; BMI — body mass index; TSH — thyroid stimulating hormone; HbA1c — glycated hemoglobin, HOMA-IR — insulin resistance (IR) index; VEGF-A — vascular endothelial growth factor A; 
1p < 0.05 vs. the control group; 2p < 0.05 vs. the Group 1; 3p < 0.05 vs. the Group 2
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old from the point of view of cardiovascular risk 
[10]. We analyzed the levels of VEGF-A in patients 
of Group 3, taking into account the levels of TTH 
up to 7.0 mIU/L and TSH levels between 7.1 and 
10.0 mIU/L. The following results were obtained: in 
patients with a slight TSH levels’ increase (up to 7.0 
mIU/L, mean value: 5.64 ± 1.07 mIU/L), VEGF-A 
levels were 382.33 ± 16.71 pg/mL, which was lower 
than those with TSH levels above 7.1 mIU/L (mean 
value: 8.87 ± 1.11 mIU/L) — 423.49 ± 21.11 pg/mL 
(p < 0.05, respectively). 
Discussion
Lipid metabolism changes in patients of different 
groups in the present study coincide with the results 
of the HUNT study, which demonstrated a direct 
relationship between the level of TSH and blood 
lipids levels, which was manifested even within the 
normal values of TSH: the higher the content of 
TSH, the higher level of cholesterol [11]. The results 
of this research confirm the existing data on the pres-
ence of atherogenic dyslipidemia on the background 
of incomplete thyroid metabolism compensation as 
a risk factor for the progression of atherosclerosis 
and, accordingly, the risk of its complications devel-
opment, as demonstrated also in a number of major 
studies [12]. The feasibility of L-thyroxine therapy in 
patients with SH is still the subject of scientific and 
practical discussions, because there are a number of 
studies that did not confirm any influence of thyroid 
subclinical hypo function on lipid metabolism [12, 
13]. However, it is indisputable the fact that for the 
treatment of dyslipidemia in hypothyroidism the use 
of the low-cholesterol diet and hypolipidemic agents 
may be insufficient.
The presence of IR in the T2DM is not in doubt; 
in the case of SH is still controversial, but for the 
combination of T2DM and SH there is virtually no 
data. Noteworthy is the fact that in studies in which 
IR in SH was not detected, the authors found hyper-
insulinemia as the first sign of glucose metabolism 
impairment. The presence of a significantly higher 
HOMA-IR in patients of Group 2 compared with 
Group 1 (patients with isolated hypertension) is ex-
pected and does not require explanation. Reducing 
this index when HT and T2DM combined with SH 
in Group 3 patients requires a deeper study of this 
issue. Perhaps this is due to the fact, that thyroid 
hormones are not only antagonists of insulin and 
exhibit counter-insular action, but according to their 
influence on peripheral tissues, they are also syner-
gists of insulin and contribute to the transportation 
and utilization of glucose. 
In recent years, it has been established that an 
increase in serum VEGF-A levels is a risk factor for 
the development of cardiovascular pathology and its 
complications. Today, VEGF-A and its physiological 
activity are of great interest and create many con-
tradictions. Its significant increase in the group of 
patients with isolated hypertension compared with 
controls in our study coincides with the available 
literature showing the important role of VEGF-A in 
the cardiovascular diseases, in particular in hyperten-
sion [2].
Vascular endothelial growth factor is an important 
bioactive substance that is involved in the develop-
ment of vascular complications in diabetes mellitus. 
However, currently available data on VEGF-A levels 
in diabetes mellitus and its complications are quite 
controversial. In the literature, there are studies that 
describe both the increase and the decrease in VEGF-
A levels in this pathology. VEGF-A has been success-
Figure 1. Vascular endothelial growth factor A (VEGF-A) levels depending on thyroid-stimulating hormone (TSH) levels (1p < 0.05 vs. controls; 
2p < 0.05 vs. HT with T2DM group; 3p < 0.05 vs. TSH 4.0–6.0 mIU/L subgroup); HT — hypertension; T2DM — type 2 diabetes mellitus
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fully used to treat ischemia with diabetic limb lesions. 
On the other hand, VEGF-A inhibition was used in 
diabetic retinopathy [4]. Lower values of VEGF-A 
in a combination of hypertension with T2DM ver-
sus isolated AH may be explained by the fact that 
in the present study, all patients with T2DM at the 
time of inclusion received Metformin. At present, 
there are numerous data, including those obtained 
in randomized trials, concerning the beneficial effects 
of Metformin on the function of endothelium [14]. 
Thus, Wu S et al. (2014) demonstrated that the use 
of Metformin over a period of 12 months resulted in 
a significant improvement in endothelium function 
[15]. The decrease in the degree of ED partially ex-
plains a decrease in the morbidity and complications 
of the CV system in patients with T2DM [16]. 
It is known that the thyroid system actively in-
teracts with different neurohumoral links involved 
in the regulation of the CV system [11 12]. Data 
on the relation between SH and ED currently re-
main controversial. The decrease in endothelium-
dependent vasodilatation (EDVD) in patients with 
hypothyroidism is supposed to be a demonstration 
of the triiodothyronine deficiency. There is also 
evidence of vascular endothelial damage under the 
influence of immune complexes on the background 
of chronic AIT, which can exacerbate the manifesta-
tions of ED.
There is evidence of a connection of high level 
of TSH with increased levels of total cholesterol, 
LDL-cholesterol and presence of ED [3].
The study of VEGF-A levels at varying degrees of 
TSH increase confirms the hypothesis of increased 
ED in hypothyroidism already at the subclinical 
level, despite the presence of factors contribut-
ing to its improvement (in the present study, the 
use of Metformin). Depression of ED occurs even 
with insignificant increase in TSH: VEGF-A level 
in subgroup with HT, T2DM and SH with TSH 
levels 4.0–6.0 mIU/L was higher than in patients 
with a combined course of hypertension and dia-
betes mellitus, but with normal thyroid function 
(375.91 ± 19.81 pg/mL and 323.94 ± 22.17pg/mL, 
respectively, p < 0.05).
Conclusions
1. Among the studied hypertensive patients with 
different concomitant diseases, ED was most pro-
nounced in patients with a combined course of 
hypertension, T2DM and SH.
2. The simultaneous course of HT and T2DM was 
accompanied by the presence of ED, which was 
manifested by elevated levels of VEGF-A com-
pared with the control group, but to a much 
lesser extent than with isolated HT, which could 
be explained by additional endothelial-protective 
effects of metformin.
3. Thyroid dysfunction, accompanied by an insig-
nificant increase in TTH, leads to a much more 
significant ED, than with comorbid states with 
normal thyroid function, which manifested in 
a significant increase in VEGF-A.
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